Fish oil derivative may calm heart inflammation and stabilize plaques
NCT ID NCT07641257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether icosapent ethyl, a purified fish oil medication, can reduce inflammation and improve heart structure in people with coronary artery disease. Researchers will follow 420 patients for one year, comparing those who receive standard care plus icosapent ethyl to those on standard care alone. They will measure blood markers of inflammation and use heart imaging to see if the drug helps stabilize fatty plaques and prevent harmful changes to the heart's shape.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
icosapent ethyl
What this could lead to
If it works, this could show that adding icosapent ethyl to standard care helps lower inflammation and stabilize heart plaques, potentially reducing future heart events.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also relatively small and short-term, so any benefits may not be confirmed or lasting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••